Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cystic Fibrosis Foundation Therapeutics, Inc.

http://www.cff.org/

Latest From Cystic Fibrosis Foundation Therapeutics, Inc.

Finance Watch: Theravance Eliminates Debt In $1.1bn Trelegy Royalty Sell-Off

Public Company Financings: Theravance sold its 85% interest in Trelegy royalties from GSK and Innoviva sold its 15% interest for up to $1.8bn in total. Also, ProKidney grossed $597m from its SPAC merger, Pliant raised $200m in a post-Phase IIa offering and Marinus earned $110m in a PRV sale.

Financing Business Strategies

ANI Plans To Shutter Oakville Plant By Q1 2023

ANI Pharmaceuticals has announced the closure of its Oakville, Ontario manufacturing plant, a move which is expected to save the firm $7m to $8m.

Strategy Manufacturing

ANI ‘On The Cusp Of A Transformation’ Following Cortrophin Launch

ANI Pharmaceuticals appeared confident about its Cortrophin gel launch and integration of Novitium Pharma as it rounded up its Q1 results, but net losses have dampened the company’s share value.

Sales & Earnings Launches

UK On Cusp Of Integrated Care And New Regulatory Fees But Innovation Adoption Pressures Remain

New medtech regulatory policy, technology adoption challenges and NHS architecture changes under the new Health and Care Act will give system UK users much to ponder over this summer.

United Kingdom Market Access
See All

Company Information

  • Industry
  • Academic and Research Institutions
UsernamePublicRestriction

Register